SCHEMBL17422006

SCHEMBL17422006

BC(CC=C)=C(CC=C)CC=C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241721 0.75 TSHR (0.43) TSHR
Ammonia Solution, Strong SCHEMBL8999729 0.72 TSHR (0.40) TSHR
SCHEMBL8231650 0.67 TSHR (0.44) TSHR
SCHEMBL8246115 0.65 TSHR (0.41) TSHR
SCHEMBL8230127 0.65 TSHR (0.33) TSHR
SCHEMBL1348616 0.62 TSHR (0.32) TSHR
SCHEMBL235460 0.62 TSHR (0.32) TSHR
SCHEMBL8254761 0.62 TSHR (0.32) TSHR
SCHEMBL1765025 0.62 TSHR (0.32) TSHR
SCHEMBL8844869 0.62 TSHR (0.35) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210247400-A1 ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF Technische Universität München (DE) 2021-08-12 US disclosed
EP-3790387-A1 ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF Technische Universität München (DE) 2021-03-17 EP disclosed
WO-2019214858-A1 ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF Technische Universität München (DE) 2019-11-14 WO disclosed
EP-3166918-B1 METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS SCINOPHARM TAIWAN LTD (TW) 2019-02-20 EP disclosed
US-9670234-B2 Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs SCINOPHARM TAIWAN, LTD. (TW) 2017-06-06 US disclosed
EP-3166918-A1 METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS Scinopharm Taiwan, Ltd. (TW) 2017-05-17 EP disclosed
WO-2016005943-A1 METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY- CYCLOPENT-2-EN-L-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS SCINOPHARM TAIWAN, LTD. (TW) 2016-01-14 WO disclosed
US-20160009740-A1 METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS SCINOPHARM TAIWAN, LTD. (TW) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009740-A1 METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS PTGIS, PTGER1, PTGS1 TSHR 3705/4885
US-20210247400-A1 ACTIVATION OF PATTERN-TRIGGERED IMMUNITY IN PLANTS BY LIPOOLIGOSACCHARID-SPECIFIC REDUCED ELICITATION (LORE) AND VARIANTS THEREOF PGLS, LIPE, LYPLA2 TSHR 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.